日本造血・免疫細胞療法学会雑誌
Online ISSN : 2436-455X
短報
Annual trends in GVHD prophylaxis using ATG in BMT and PBSCT in Japan
Souichi ShiratoriMarie OhbikiNoriko DokiTakahiro FukudaSatoshi YoshiharaYoshinobu KandaTetsuya NishidaNoboru AsadaHirohisa NakamaeYuta HasegawaYoshiko AtsutaTakanori Teshima
著者情報
ジャーナル フリー

2025 年 14 巻 2 号 p. 110-113

詳細
抄録

 Graft-versus-host disease (GVHD) prophylaxis using antithymocyte globulin (ATG) has been well-established in allogeneic hematopoietic stem cell transplantation. We collected data on GVHD prophylaxis from 27,091 cases of hematological malignancies undergoing bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from 2010 to 2022. Annual trends in GVHD prophylaxis were analyzed based on donor type, stem cell source or HLA compatibility. The number of GVHD prophylaxis using ATG was increased in related-HLA matched-PBSCT [2010: n=6 (1.6%), 2022: n=42 (14.1%)], unrelated-HLA matched-PBSCT [2010: n=0 (0.0%), 2022: n=80 (43.0%)], unrelated-HLA 1-locus mismatched-BMT [2010: n=36 (9.6%), 2022: n=97 (40.4%)], and unrelated-HLA 1-locus mismatched-PBSCT [2010: n=0 (0.0%), 2022: n=64 (59.3%)]. Conversely, ATG use decreased in related-HLA haplo-PBSCT [2010: n=111 (67.7%), 2022: n=63 (11.2%)] due to the increasing use of posttransplant cyclophosphamide (PTCy). This study highlights the variation in GVHD prophylaxis trends using ATG across transplantation types.

著者関連情報
© 2025 Japanese Society for Transplantation and Cellular Therapy
前の記事
feedback
Top